Vensana Capital raises $ 325 million and expands team to support transformative medical technology innovations
MINNEAPOLIS & WASHINGTON – (COMMERCIAL THREAD) – Vensana Capital today announced the closing of its second fund, Vensana Capital II, with committed capital of $ 325 million. The fund was oversubscribed to its hard cap with the support of the company’s investors in its inaugural fund alongside selected new institutional investors.
Vensana Capital was launched in 2019 as a venture capital and growth capital investment firm dedicated to partnering with innovative medical technology companies in their development and commercial phases. Medtech sub-sectors of interest to the company include medical devices, diagnostics and data science, life science tools, digital health, and technology services. Since its inception, Vensana has been recognized as one of the most active investors in its areas of interest with a diverse portfolio of companies offering top notch and premier products. The company has made 10 investments to date, including Intact Vascular, acquired last year by Philips, and CVRx, which has just completed its IPO.
Vensana co-founders Justin Klein, MD, JD and Kirk Nielsen are joined by a team of experienced investment professionals, including Principal Cynthia Yee and Vice President Greg Banker, along with recent additions to the Venture Partner Mike Kramer and Principal Amrinder Singh, in addition to CFO. Steve Schwen. Mike joined the company earlier this year from healthcare investment firm CRG after several senior operating roles at public and private medical technology companies, and Amrinder recently joined Medtronic Ventures after various positions at Medtronic and Thoratec. Both provide complementary expertise in healthcare investment, operations and strategy. Vensana’s investment team is further bolstered by an advisory board made up of more than two dozen senior medical technology executives, entrepreneurs and subject matter experts.
“We are proud of the progress Vensana has made since its inception, particularly our growing investment team and our portfolio of companies meeting significant unmet needs, and we are grateful for the strong and continued support of our sponsors, âsaid Managing Partner Kirk Nielsen. “Our entire team is excited about the opportunity before us as we work hard to create a platform for investment and business creation in leading medical technologies.”
âMedical technological innovations have the potential to dramatically improve the quality and outcomes of healthcare while reducing costs. We believe Vensana has both a tremendous opportunity and a responsibility to support our entrepreneurs in their quest for technologies and businesses that will transform healthcare for the future, âsaid Managing Partner Justin Klein, MD, JD
About Vensana Capital
Vensana Capital is a venture capital and growth capital investment firm dedicated to building partnerships with entrepreneurs seeking to transform healthcare through groundbreaking innovations in medical technology. Launched in 2019, Vensana actively invests in development and commercial stage companies in the medical technology industry, including medical devices, diagnostics and data science, life science tools, digital health and technological services. Vensana’s investment team has a history of successful partnership with management teams behind industry-leading companies including Cameron Health, CardiAQ, Cartiva, CV Ingenuity, CVRx, Epix Therapeutics, Inari Medical, Intact Vascular, Lutonix, Neuwave Medical, Respicardia, Sequent Medical, Topera, Ulthera, Veran Medical Technologies, and Vertiflex. Learn more at www.vensanacap.com.